journal
https://read.qxmd.com/read/36948678/the-progession-landscape-of-diagnostic-and-treatment-options-for-kidney-cancer
#1
EDITORIAL
Steven L Chang, Michael L Blute
No abstract text is available yet for this article.
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948677/when-you-hear-hoofbeats-sometimes-think-of-zebras
#2
EDITORIAL
Kevin R Loughlin
No abstract text is available yet for this article.
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948676/the-changing-landscape-of-immunotherapy-for-advanced-renal-cancer
#3
REVIEW
Soki Kashima, David A Braun
The management of advanced renal cell carcinoma has advanced tremendously over the past decade, but most patients still do not receive durable clinical benefit from current therapies. Renal cellcarcinoma is an immunogenic tumor, historically with conventional cytokine therapies, such as interleukin-2 and interferon-α, and contemporarily with the introduction of immune checkpoint inhibitors. Now the central therapeutic strategy in renal cell carcinoma is combination therapies including immunecheckpoint inhibitors...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948675/radiation-therapy-in-the-treatment-of-localized-and-advanced-renal-cancer
#4
REVIEW
Kendrick Yim, Jonathan E Leeman
Renal cell carcinoma (RCC) has historically been considered resistant to radiotherapy. However, advances in the field of radiation oncology have led to safe delivery of higher radiation doses through the use of stereotactic body radiotherapy (SBRT) that have shown significant activity against RCC. SBRT has now been shown to be a highly effective modality for management of localized RCC for nonsurgical candidates. Increasing evidence also points to a role for SBRT in the management of oligometastatic RCC as a means for not only providing palliation but prolonging time to progression and potentially improving survival...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948674/integrating-surgery-in-the-multidisciplinary-care-of-advanced-renal-cell-carcinoma
#5
REVIEW
Shagnik Ray, Shawn Dason, Eric A Singer
The role of surgery for patients with locally advanced and metastatic renal cell carcinoma (RCC) is not precisely defined in our contemporary era of systemic therapies. Research in this field is focused on the role of regional lymphadenectomy, along with indications and timing of cytoreductive nephrectomy and metastasectomy. As our understanding of the molecular and immunological basis of RCC continues to develop along with the advent of novel systemic therapies, prospective clinical trials will be critical in defining how surgery should be integrated into the treatment paradigm of advanced RCC...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948673/the-great-masquerader-s-new-wardrobe-in-the-modern-era-the-paraneoplastic-manifestations-of-renal-cancer
#6
REVIEW
Kevin R Loughlin
Paraneoplastic syndromes can occur in 8% to 20% of individuals with malignancies. They can occur in a variety of cancers that include breast, gastric, leukemia, lung, ovarian, pancreatic, prostate, testicular, as well as kidney. The classic presentation of the triad of mass, hematuria, and flank pain occurs in less than 15% of patients with renal cancer. Because of the protean presentations of renal cell cancer, it has been referred to as the internist's tumor or the great masquerader. This article will provide a review of the causes of these symptoms...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948672/the-promise-of-neoadjuvant-and-adjuvant-therapies-for-renal-cancer
#7
REVIEW
Jeffrey J Leow, Shagnik Ray, Shawn Dason, Eric A Singer, Steven L Chang
Because metachronous metastatic disease will develop in 20% to 40% of patients with presumed localized renal cell carcinoma (RCC) treated surgically, research is focused on neoadjuvant and adjuvant systemic therapy, to improve disease-free and overall survival. Neoadjuvant therapies trialed include anti-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) agents, or combination therapies (immunotherapy with TKI), and aim to improve resectability of locoregional RCC. Adjuvant therapies trialed include cytokines, anti-VEGF TKI agents, or immunotherapy...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948671/surgical-management-of-renal-cell-carcinoma-with-inferior-vena-cava-tumor-thrombus
#8
REVIEW
Shawn Dason, Jahan Mohebali, Michael L Blute, Keyan Salari
Most kidney cancers are primary renal cell carcinomas (RCC) of clear cell histology. RCC is unique in its ability to invade into contiguous veins - a phenomenon terms venous tumor thrombus. Surgical resection is indicated for most patients with RCC and an inferior vena cava (IVC) thrombus in the absence of metastatic disease. Resection also has an important role in selected patients with metastatic disease. In this review, we discuss the comprehensive management of the patient with RCC with IVC tumor thrombus, emphasizing a multidisciplinary approach to the surgical techniques and perioperative management...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948670/long-term-renal-function-following-renal-cancer-surgery-historical-perspectives-current-status-and-future-considerations
#9
REVIEW
Andrew M Wood, Tarik Benidir, Rebecca A Campbell, Nityam Rathi, Robert Abouassaly, Christopher J Weight, Steven C Campbell
Knowledge of functional recovery after partial (PN) and radical nephrectomy for renal cancer has advanced considerably, with PN now established as the reference standard for most localized renal masses. However, it is still unclear whether PN provides an overall survival benefit in patients with a normal contralateral kidney. While early studies seemingly demonstrated the importance of minimizing warm-ischemia time during PN, multiple new investigations over the last 10 years have proven that parenchymal mass lost is the most important predictor of new baseline renal function...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948669/cystic-renal-masses-old-and-new-paradigms
#10
REVIEW
Majed Alrumayyan, Lucshman Raveendran, Keith A Lawson, Antonio Finelli
Cystic renal masses describe a spectrum of lesions with benign and/or malignant features. Cystic renal masses are most often identified incidentally with the Bosniak classification system stratifying their malignant potential. Solid enhancing components most often represent clear cell renal cell carcinoma yet display an indolent natural history relative to pure solid renal masses. This has led to an increased adoption of active surveillance as a management strategy in those who are poor surgical candidates...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948668/the-changing-role-of-renal-mass-biopsy
#11
REVIEW
Sohrab Naushad Ali, Zachary Tano, Jaime Landman
The incidence and prevalence of small renal masses (SRMs) continues to rise and with increased detection comes increases in surgical management, although the probability of an SRM being benign is upward of 30%. An extirpative treatment first diagnose-later strategy persists and clinical tools for risk stratification such as renal mass biopsy remain severely underutilized. The overtreatment of SRMs has multiple detrimental effects including surgical complications, psychosocial stress, financial loss, and reduced renal function leading to downstream effects such as the need for dialysis and cardiovascular disease...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948667/diseases-of-hereditary-renal-cell-cancers
#12
REVIEW
Othon Iliopoulos
Germline mutations in tumor suppressor genes and oncogenes lead to hereditary renal cell carcinoma (HRCC) diseases, characterized by a high risk of RCC and extrarenal manifestations. Patients of young age, those with a family history of RCC, and/or those with a personal and family history of HRCC-related extrarenal manifestations should be referred for germline testing. Identification of a germline mutation will allow for testing of family members at risk, as well as personalized surveillance programs to detect the early onset of HRCC-related lesions...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948666/biomarkers-for-the-detection-and-surveillance-of-renal-cancer
#13
REVIEW
José Ignacio Nolazco, Simon John Christoph Soerensen, Benjamin I Chung
Renal cell carcinoma (RCC) is a heterogeneous disease characterized by a broad spectrum of disorders in terms of genetics, molecular and clinical characteristics. There is an urgent need for noninvasive tools to stratify and select patients for treatment accurately. In this review, we analyze serum, urinary, and imaging biomarkers that have the potential to detect malignant tumors in patients with RCC. We discuss the characteristics of these numerous biomarkers and their ability to be used routinely in clinical practice...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948665/evolution-in-the-pathologic-classification-of-renal-neoplasia
#14
REVIEW
Reza Alaghehbandan, Steven C Campbell, Jesse K McKenney
The pathologic classification of renal tumors is a dynamic and complex process, which has evolved to a "histomolecular" driven system. Despite advances in molecular characterization, most renal tumors can be diagnosed by morphology with or without using a limited set of immunohistochemical stains. If access to molecular resources and specific immunohistochemical markers is limited, pathologists may face difficulties in following an optimal algorithm to classify renal tumors. In this article, we detail the historical evolution of renal tumor classification, including a synopsis of major changes introduced by the current fifth edition World Health Organization 2022 classification of renal epithelial tumors...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36948664/radiologist-s-disease-imaging-for-renal-cancer
#15
REVIEW
Alex Chung, Steven S Raman
There is a clear benefit of imaging-based differentiation of small indeterminate masses to its subtypes of clear cell renal cell carcinoma (RCC), chromophobe RCC, papillary RCC, fat poor angiomyolipoma and oncocytoma because it helps determine the next step options for the patients. The work thus far in radiology has explored different parameters in computed tomography, MRI, and contrast-enhanced ultrasound with the discovery of many reliable imaging features that suggest certain tissue subtypes. Likert score-based risk stratification systems can help determine management, and new techniques such as perfusion, radiogenomics, single-photon emission tomography, and artificial intelligence can add to the imaging-based evaluation of indeterminate renal masses...
May 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36424088/progress-and-promise-of-biomarker-discovery-and-development-in-urologic-disease
#16
EDITORIAL
Adam S Feldman
No abstract text is available yet for this article.
February 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36424087/the-continued-pursuit-of-urologic-biomarkers-beyond-prostate-specific-antigen
#17
EDITORIAL
Kevin R Loughlin
No abstract text is available yet for this article.
February 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36424086/combined-use-of-magnetic-resonance-imaging-and-biomarker-testing-to-detect-clinically-significant-prostate-cancer
#18
REVIEW
Nathan L Samora, Bashir Al Hussein Al Awamlh, Jeffrey J Tosoian
We performed a narrative review of studies that produced clinically applicable data by examining the combined use of at least one biomarker test and multiparametric MRI to predict GG ≥2 prostate cancer on biopsy and by reporting the resultant clinical outcomes (i.e, the proportion of biopsies avoided and GG ≥2 cancers missed) following the application of various testing strategies incorporating these diagnostic tests.
February 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36424085/the-association-between-the-urinary-microbiome-and-bladder-cancer
#19
REVIEW
Ahmed A Hussein, Gary Smith, Khurshid A Guru
Many studies are currently investigating the association between the urinary microbiome and bladder cancer, focusing on differences between stages and with risk of recurrence and progression. However, many of these studies are limited by the small number of patients, presence of confounders and issues with sampling, DNA extraction, and analyses. Recently there has been a shift toward examining the microbiome of bladder tissues rather than urine samples; however, these studies remain a minority. Identification of the differences in microbiome composition between different stages of bladder cancer can provide biomarkers to identify the patients who are more likely to respond to intravesical treatment...
February 2023: Urologic Clinics of North America
https://read.qxmd.com/read/36424084/biological-stratification-of-invasive-and-advanced-urothelial-carcinoma
#20
REVIEW
Moritz J Reike, Alberto Contreras-Sanz, Peter C Black
Muscle-invasive urothelial carcinoma (UC) of the bladder remains a highly lethal malignancy. In this review the authors explore the underlying biology associated with the evolution from non-muscle-invasive UC to muscle-invasive and metastatic UC, with a special focus on the molecular stratification of UC and the potential of this stratification to be used for treatment selection.
February 2023: Urologic Clinics of North America
journal
journal
25018
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.